Lokalize Mide Kanseri Nedeniyle Adjuvan Kemoradyoterapi Uygulanan Hastalarda p53 Ekspresyonun Prognostik Önemi

Year 2013, Volume: 14 Issue: 1, 23 - 29, 01.04.2013

Duriye Öztürk , Mustafa Yıldırım Evrim Duman Arsenal Sezgin Alikanoğlu Ayşe Yıldırım Mustafa Yıldız Cem Sezer

Abstract

Objective: The postopreative standard therapy in gastric cancer is 5FU based chemotherapy and concurrent 45 Gy external radiothearpy , nowadays. The high rates of toxicity of this thearpy causes discontiniuty in majority of the patients. These side effects can be prevented by predicting the response to therapy by the help of some spesisfic clinical and laboratory parameters determined at the time of diagnosis. In our study the prognostic and -if there is the predictive role of p53 expression in patients with gastric cancer who had adjuvant chemotherapy has been searched. Material and Methods: Patients with a postoperative histopathologic diagnosis and who had adjuvant chemoradiotherapy in Medical Oncology and local Radiation Oncology Departments of Antalya Eucation and Research Hospital between 2008-2011 were enrolled in this study. immunohistochemical method. Results: A total of 20 patients , (11 (%52,4) male and 9 (%42,9) female) were enrolled in the study. p53 expression was found positive in 13 (%61,9) patients and negative in 7 (%33,3)patients. Median survival time ws found 12.2 months in p53 negaive patients and 11 months in p53 positive patients. A significant relationship was not found between p53 expression and survival. (P:0,781). Conclucion: Although we were not able to show the predictive role of p53 expression in this patient group in this study, we think that new studies including determining p53 in blood samples will be helpful in explaining some unknown things about this issue

Keywords

Gastric cancer; chemoradiotherapy; p53

Lokalize Mide Kanseri Nedeniyle Adjuvan Kemoradyoterapi Uygulanan Hastalarda p53 Ekspresyonun Prognostik Önemi

Abstract

Amaç: Günümüzde mide kanserinde postoperatif yaklaşımda standart tedavi 5FU bazlı kemoterapi ve eş zamanlı 45 Gy eksternal radyoterapidir. Bu tedavinin yüksek toksisite oranları hastaların büyük çoğunluğunun tedavisin-de kesintiye sebep olmaktadır. Tanı sırasında saptanabilen bazı klinik ve laboratuar parametreleri kullanılarak; tedaviye yanıtının tahmin edilmesi ile bu yan etkilerden kaçınılabilinir. Çalışmamızda mide kanseri nedeniyle adjuvan kemoradyoterapi uyguladığımız hastalarda p53 ekspresyonun prognostik ve varsa prediktif rolü araştırıldı. Gereç ve Yöntem: 2008-2011 yılları arasında Antalya Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji ve yerel Radyasyon Onkolojisi kliniklerinde postoperatif histopatolojik olarak tanısı doğrulanmış adjuvan kemoradyoterapi almış olan hastalar çalışmaya dahil edildi. p53 ekspresyonu immünohistokimya ile araştırıldı. Bulgular: Çalışmaya 11’i (%52,4) erkek, 9’u (%42,9) kadın olmak üzere toplam 20 hasta alındı. p53 ekspresyonu 13 hastada (%61,9) hastada pozitif olarak saptanırken 7 hastada (%33,3) negatif olarak saptandı. Hastaların medyan yaşam süresi p53 negatiflerde 12.2 ay, p53 pozitif olanlarda 11 ay olarak saptandı. p53 ekspresyonu ile sağkalım arasında ilişki tespit edilemedi (P:0,781). Sonuç: Çalışmamızda p53 ekspresyonun bu hasta grubunda prediktif rolünü gösterememize rağmen hasta serum örneklerinde p53’ün tespit edilmesini de içeren yeni çalışmaların bu konudaki bilinmeyenleri aydınlatacağını düşünüyoruz

Keywords

Mide kanseri; kemoradyoterapi; p53

References

• Catalano V, Labianca R, Bretta GD, et al. Gastric Cancer 2009;71(2):127-64.
• Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics 2002. CA Cancer J Clin 2005;55:74–108.
• Nakamura K, Ueyama T, Xuan ZX, et al. Pathology and Prognosis of Gastric Carcinoma. Findings in 10,000 Gastrectomy. Cancer 1992;70:1030-7. Who Underwent Primary
• Tsujitani S, Saito H, Wakatsuki T, et al. Relationship Between Expression of Apoptosis-Related Proteins and the Efficacy of Postoperative Chemotherapy in Patients with T3 Gastric Cancer. Surg Today 2012;42(3):225-32.
• Rajdev L. Treatment Options for Surgically Resectable Gastric Cancer. Current Treatment Options in Oncology 2010;11(1-2):13-23.
• Macdonald JS, Smalley S, Benedetti J, et al. Chemoradiotherapy After Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal 2001;345(10):725-30. N Eng J Med
• Sakuramoto S, Yamashita K, Watanabe M. Newly Emerging Standard Chemotherapies for Gastric Cancer and Clinical Potential in Elderly Patients. World J Gastointestinal Oncol 2009;1(1):47-54.
• Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic Significance of p53 Overexpression in Gastric and Colorectal Carcinoma. Br J Cancer 1992;66(3):558-62.
• Mide kanserinde kemoradyoterapi Chemoradiotherapy in gastric cancer Kerns BJ, Jordan PA, Moore MB, et al. p53 Overexpression in Formalin-Fixed, Paraffin-Embedded Tissue J Histochem Cytochem 1992;40(7):1047-51. by
• İmmunohistochemistry. Radovanović D, Knezević M, Canović D, Aćimović L. Correlation between p53 Expression and Clinical- Pathological Characteristics of Gastric Cancer. Vojnosanit Pregl 2011;68(10):832-6.
• Zhang J, He XH, Xie XY, Hu X, He C. The Potential for Serum p53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer. J Int Med Res 2010;38(2):423-31.
• Lim MS, Lee HW, Im H, et al. Predictable Factors for Lymph Node Metastasis in Early Gastric Cancer- Analysis of Single İnstitutional Experience. J Gastrointest Surg 2011;15(10):1783-8.
• Song KY, Jung CK, Park WS, Park CH. Expression of the Antiapoptosis Gene Survivin Predicts Poor Prognosis of Stage III Gastric Adenocarcinoma. Jpn J Clin Oncol 2009;39(5):290-6.
• Chen GX, Zheng LH, Liu SY, He XH. rAd-p53 Enhances the Sensitivity of Human Gastric Cancer Cells to Chemotherapy. World J Gastroenterol 2011;17(38):4289-97.
• Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup. Surgical Treatment Variation in a Prospective, Randomized Trial of Chemoradiotherapy in Gastric Cancer: the Effect of Undertreatment. Ann Surg Oncol 2002;9(3):278-86.
• Sirak I, Petera J, Hatlova J, et al. Expression of p53, p21 and p16 Does not Correlate with Response to Preoperative Chemoradiation in Gastric Carcinoma. Hepatogastroenterology 2009;56(93):1213-8.
• Ito T, Kaneko K, Makino R, et al. Prognostic Value of p53 Mutations in Patients with Locally Advanced Esophageal Carcinoma Treated with Definitive Chemoradiotherapy. J Gastroenterol 2001;36(5):303